Browse by Journal Title

2022

Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
Kaddu-Mulindwa, D., Lesan, V., Berdel, C., Stilgenbauer, S., Bewarder, M., Thurner, L., Witzens-Harig, M., Viardot, A., Soekler, M., Keller, U., Truemper, L., Christofyllakis, K., Fleser, O., Bittenbring, J.T., Poeschel, V., Held, G. and Jagoda, P.
Leukemia & Lymphoma 63 (2): 326-334. February 2022

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Denker, S., Bittner, A., Frick, M., Kase, J., Hoffmann, J., Trenker, C., Keller, U., Bogner, C., Hüttmann, A., Dürig, J., Janz, M., Mathas, S., Marks, R., Krohn, U., Na, I.K., Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 63 (1): 84-92. January 2022

2021

Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient.
Bittner, A., Radke, J., Eurich, D., Wiener, E., Denker, S., Anagnostopoulos, I., Na, I.K., Heppner, F.L., Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 62 (8): 2026-2029. August 2021

2017

Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
Bohl, S.R., Dolnik, A., Jensen, T., Lang, K.M., Hackanson, B., Gaidzik, V.I., Paschka, P., Knudsen, S., Döhner, K., Döhner, H., Claus, R., Lübbert, M. and Bullinger, L.
Leukemia & Lymphoma 58 (9): 2264-2267. 2 September 2017

2015

Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.
Kaeda, J., Ringel, F., Oberender, C., Mills, K., Quintarelli, C., Pane, F., Koschmieder, S., Slany, R., Schwarzer, R., Saglio, G., Hemmati, P., van Lessen, A., Amini, L., Greese, M., Vagge, E., Burmeister, T., Serra, A., Carson, A., Schwarz, M., Westermann, J., Jundt, F., Doerken, B. and le Coutre, P.
Leukemia & Lymphoma 56 (7): 2105-2113. July 2015

Differential expression of SHP-1 in chronic myeloid leukemia.
Kaeda, J., Neuman, D., Bonecker, S., Mills, K., Oberender, C., Amini, L., Ringel, F., Serra, A., Schwarz, M., Doerken, B., Zalcberg, I. and Le Coutre, P.
Leukemia & Lymphoma 56 (5): 1547-1549. May 2015

2014

JAK2 V617F allele burden quantified by real time quantitative polymerase chain reaction and competitive polymerase chain reaction in patients with chronic myeloproliferative neoplasia.
Kaeda, J., Bonamino, M., Ayres-Silva, J., Solza, C., Ringel, F., Blau, O., Daumas, A., Oberender, C., Doerken, B., Le Coutre, P. and Zalcberg, I.
Leukemia & Lymphoma 55 (1): 128-135. January 2014

2013

Sequencing of NUMB transcripts in chronic myeloid leukaemia detects two single nucleotide polymorphisms.
Oberender, C., Kaeda, J., Pawlaczyk-Peter, B., Daniel, P., Arnold, R., Doerken, B. and le Coutre, P.
Leukemia & Lymphoma 54 (2): 421-422. February 2013

2011

Long-term follow-up of patients with Philadelphia chromosome-positive chronic myeloid leukemia after stem cell mobilization under imatinib.
Kim, T.D., Schwarz, M., Kreuzer, K.A., Kaeda, J., Movassaghi, K., Grille, P., Daniel, P.T., Doerken, B. and le Coutre, P.
Leukemia & Lymphoma 52 (3): 517-520. March 2011

2000

Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA-identical related donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8.
Ratei, R., Matylis, A., Krahl, D., Arnold, R., Stein, H., Doerken, B. and Ludwig, W.D.
Leukemia & Lymphoma 40 (1-2): 133-140. December 2000

1999

Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance.
Schwartz, S., Heinecke, A., Zimmermann, M., Creutzig, U., Schoch, C., Harbott, J., Fonatsch, C., Loeffler, H., Buechner, T., Ludwig, W.D. and Thiel, E.
Leukemia & Lymphoma 34 (1-2): 85-94. June 1999

1995

Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML.
Sperling, C., Buechner, T., Creutzig, U., Ritter, J., Harbott, J., Fonatsch, C., Sauerland, C., Mielcarek, M., Maschmeyer, G., Loeffler, H. and Ludwig, W.D.
Leukemia & Lymphoma 17 : 417-426. 1 January 1995

1994

Immunophenotypic features of childhood and adult acute lymphoblastic leukemia (ALL): experience of the German Multicentre Trials ALL-BFM and GMALL.
Ludwig, W.D., Reiter, A., Loeffler, H., Goekbuget, N., Hoelzer, D., Riehm, H. and Thiel, E.
Leukemia & Lymphoma 13 Suppl. 1 : 71-76. 1 January 1994

Combined immunophenotyping and karyotyping in peripheral T cell lymphomas demonstrating different clonal and nonclonal chromosome aberrations in T helper cells.
Schlegelberger, B., Weber-Matthiesen, K., Sterry, W., Bartels, H., Sonnen, R., Maschmeyer, G., Feller, A.C. and Grote, W.
Leukemia & Lymphoma 15 : 113-125. 1 January 1994

1993

The role of GM-CSF in the treatment of acute myeloid leukemia.
Buechner, T., Hiddemann, W., Woermann, B., Rottmann, R., Maschmeyer, G., Ludwig, W.D., Zuehlsdorf, M., Buntkirchen, K., Sander, A., Aswald, J., Binder, I., Prisett, S. and Sauerland, M.C.
Leukemia & Lymphoma 11 Suppl. 2 : 21-24. 1 January 1993

High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Hiddemann, W., Aul, C., Maschmeyer, G., Schoenrock-Nabulsi, R., Ludwig, W.D., Bartholomaeus, A., Bettelheim, P., Becker, K., Balleisen, L., Lathan, B., Koeppler, H., Grueneisen, T., Donhuijsen-Ant, R., Reichle, A., Heinecke, A., Sauerland, C. and Buechner, T.
Leukemia & Lymphoma 10 Suppl. : 133-137. 1 January 1993

1992

AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment.
Maschmeyer, G., Willborn, K. and Heit, W.
Leukemia & Lymphoma 8 : 365-369. 1 January 1992